Shire Introduces Vyvanse Capsules
Posted on: Wednesday, 23 July 2008, 09:01 CDT
Shire, a specialty biopharmaceutical company, has launched Vyvanse for the treatment of adults with attention deficit hyperactivity disorder.
This launch follows the recent FDA approval of Vyvanse to treat attention deficit hyperactivity disorder (ADHD) in the adult population. Vyvanse is now available in US pharmacies nationwide in six once-daily dosage strengths.
Shire received approval in April 2008 from the FDA for Vyvanse for the treatment of ADHD in adults aged 18 to 55 years. Vyvanse is available in six dosage strengths of 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg.
To raise awareness of ADHD in adults and recognize the launch of Vyvanse for adults, Shire has also partnered with celebrity designer Ty Pennington to shine the spotlight on living as an adult with ADHD.
Source: Datamonitor
Related Articles
- Shire Initiates Two Adult ADHD Outreach Programs
- VYVANSE CII Shows Significant Efficacy At 14 Hours In Adults With ADHD
- Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
- Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (Lisdexamfetamine Dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults With ADHD
- Celebrity Designer and ADHD Spokesperson Ty Pennington Partners With Shire to Announce the Launch of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
- Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (Lisdexamfetamine Dimesylate) As a Novel Treatment for ADHD
- FDA Approves Shire's ADHD Drug Vyvanse
- Shire Seeks Approval for New ADHD Drug
- Shire Plc - Statement Regarding the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting
 |
 |
User Comments (0)
RSS Feeds